- Europe, like you've never read before -
Tuesday, 17 November 2026
No Result
View All Result
  • en ENG
  • it ITA
Eunews
  • Politics
  • World
  • Business
  • News
  • Defence
  • Health
  • Agrifood
  • Other sections
    • Culture
    • Rights
    • Energy
    • Green Economy
    • Finance & Insurance
    • Industry & Markets
    • Media
    • Mobility & Logistics
    • Net & Tech
    • Sports
  • European 2024
    Eunews
    • Politics
    • World
    • Business
    • News
    • Defence
    • Health
    • Agrifood
    • Other sections
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • Sports
    No Result
    View All Result
    Eunews
    No Result
    View All Result

    Home » Health » The Commission has authorised Daraxonrasib, a treatment for pancreatic cancer

    The Commission has authorised Daraxonrasib, a treatment for pancreatic cancer

    Iolanda Cuomo by Iolanda Cuomo
    17 November 2026
    in Health, In Brief
    Medicinali. Crediti: Roberto

    Medicinali. Crediti: Roberto Sorin via Unsplash

    Brussels – The European Commission today (17 November) granted marketing authorisation to the marketing authorisation for Daraxonrasib in the European Union, a new anti-tumour medicine for metastatic pancreatic cancer. The medicine may be used to treat adult patients who have already undergone at least one previous course of treatment. In line with the EU’s pharmaceutical reform, the medicine underwent accelerated regulatory procedures, without compromising the “Union’s rigorous standards of safety, quality, and efficacy.” This involved a streamlined review by the European Medicines Agency (EMA), which issued a positive scientific assessment in just over 100 days. This is almost half the time required under the previous legal deadline of 210 days. The newly authorised medicine could address what has been described as “an unmet medical need,” as it targets a serious disease for which better treatment options are required. For this reason, it has been designated a “high-priority medicine” under the EMA’s Cancer Medicines Pathfinder programme, which, launched in 2023, focuses on patient care and access to innovative therapies. 

    Daraxonrasib is also the subject of an ongoing
    joint clinical assessments

    (JCA) by the Member States’ Co-ordination Group on Health Technology Assessment. These assessments enable EU Member States to collaborate in evaluating the clinical benefits of new medicines and certain medical devices, thereby reducing duplication, saving time and resources, and providing companies with a clearer and more predictable process. At present, work on the JCA report is being fast-tracked to make it available in December, in order to facilitate its access across the Union. The JCAs were established by Regulations on the assessment of health technologies (HTA) with the aim of supporting Member States’ national health technology assessment processes by providing a scientific analysis of the clinical evidence relating to the effects of a health technology (a medicinal product or a medical device) on health outcomes.

    English version by the Translation Service of Withub
    Tags: Agenzia europea dei medicinalicancerpalazzo berlaymont

    Related Posts

    L'Eurocamera approva il Piano contro il cancro, ma la riforma europea del tabacco si ferma al vaglio tecnico
    Health

    The European Parliament approves the Cancer Plan, but the European tobacco reform has stalled at the technical review stage

    12 November 2026
    Parlamento europeo. Crediti: Jonas Horsch via Pexels
    Health

    On the eve of the vote, the EPP remains divided over the Plan against Cancer. Zdechovský: “The text reflects the priorities of the left too closely”

    11 November 2026
    PPE BECA parlamento europeo
    Health

    BECA, unease within the EPP: “Backing this text would be a serious political mistake”

    3 November 2026
    PETER HEGEMANN BIOFISICO TEDESCO VINCITORE DEL PREMIO NOBEL PER LA FISIOLOGIA O LA MEDICINA 2026
    Health

    Peter Hegemann, winner of the 2026 Nobel Prize in Medicine, has received EU funding for his research

    6 October 2026
    map visualization

    Russia at the Olympics: the EU is working on countermeasures and is clashing with the IOC

    by Emanuele Bonini emanuelebonini
    17 November 2026

    High Representative Kallas: “We are drawing up proposals aimed at restricting the Federation’s participation in sporting events”

    Medicinali. Crediti: Roberto

    The Commission has authorised Daraxonrasib, a treatment for pancreatic cancer

    by Iolanda Cuomo
    17 November 2026

    Brussels – The European Commission today (17 November) granted marketing authorisation to the marketing authorisation for Daraxonrasib in the European...

    L'UE alla COP31: "È il momento di attuare gli impegni, non di introdurre nuove regole" - Hoekstra e O'Brien

    The EU at COP31: “Now is the time to deliver on our commitments, not to introduce new rules”

    by Annachiara Magenta annacmag
    17 November 2026

    At the heart of European concerns is the first draft of the Cover Decision prepared by the Presidency, an 18-page...

    Caccia. Crediti: 
BĀBI via Unsplash

    New EU rules to restrict the use and sale of lead-containing shotgun pellets

    by Iolanda Cuomo
    17 November 2026

    Brussels – Lead is harmful to health, but there are still items that contain it. Today (17 November), the European...

    • Director’s Point of View
    • Opinions
    • About us
    • Contacts
    • Privacy Policy
    • Cookie policy

    Eunews is a registered newspaper
    Press Register of the Court of Turin n° 27

    Copyright © 2025 - WITHUB S.p.a., Via Savona 127/B, 20144 Milano
    VAT number: 10067080969 - ROC registration number n.30628
    Fully paid-up share capital 50.000,00€

     

    No Result
    View All Result
    • en ENG
    • it ITA
    • Politics
    • Newsletter
    • World politics
    • Business
    • General News
    • Defence & Security
    • Health
    • Agrifood
    • Altre sezioni
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Gallery
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • News
      • Opinions
      • Sports
    • Director’s Point of View
    • Draghi Report
    • Eunews Newsletter

    No Result
    View All Result
    • en ENG
    • it ITA
    • Politics
    • Newsletter
    • World politics
    • Business
    • General News
    • Defence & Security
    • Health
    • Agrifood
    • Altre sezioni
      • Culture
      • Rights
      • Energy
      • Green Economy
      • Gallery
      • Finance & Insurance
      • Industry & Markets
      • Media
      • Mobility & Logistics
      • Net & Tech
      • News
      • Opinions
      • Sports
    • Director’s Point of View
    • Draghi Report
    • Eunews Newsletter

    Attention